Corporate Profile
We are a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
Our initial focus is on developing our novel and proprietary 5-Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment Resistant Depression, or TRD.
Our lead product candidate, GH001, is formulated for 5-MeO-DMT administration via a proprietary inhalation approach. With GH001, we have completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). Based on the observed clinical activity, where 87.5% of patients with TRD were brought into an ultra-rapid remission with our GH001 individualized single-day dosing regimen in the Phase 2 part of the trial, we believe that GH001 has potential to change the way TRD is treated today.
Our portfolio also includes GH002 and GH003, our proprietary injectable and intranasal 5-MeO-DMT product candidates.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
SEC Filings
| Filing date | Description | Form |
|---|---|---|
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K | |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K | |
Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act |
6-K |